At EG427 our unique, non-replicative Herpes Simplex Virus type 1 (HSV-1) based vector platform delivers, with pinpoint precision, highly selective, durable expression of disease modifying transgenes for use in the treatment of peripheral nervous system disorders and beyond. Our lead asset EG110A, for the treatment of neurogenic bladder dysfunction, is expected to be in the clinic by early 2024. Our revolutionary approach to the treatment of this disease aims at providing patients with a comprehensive, long-term solution to their bladder management, through a highly selective molecular biology approach overcoming the drawbacks of current standard of care. Our HQ and labs are in Paris, France, where we were founded in 2019. We have raised over USD 15 million, including from our Series A in 2021.
Employees: 1-10
Total raised: $20.2M
Founded date: 2019
Funding Rounds 1
| Date | Series | Amount | Investors |
| 14.07.2023 | Series A | $20.2M | - |
Mentions in press and media 8
| Date | Title | Description |
| 24.06.2024 | First gene therapy for prevalent pathologies in neurology receives FDA IND clearance - EG 427 initiating first-in-human clinical study | EG110A to start Phase 1b/2a clinical study in Neurogenic Detrusor Overactivity (NDO) patients NDO is a severe bladder condition affecting millions of patients living with Spinal Cord Injury, Multiple Sclerosis, Parkinson’s disease and other... |
| 10.11.2023 | Which Parisian Biotech Startups are Pioneering Industry Innovations in 2023? | Paris, the global hub for art, fashion, gastronomy, and culture is now extensively recognized for its astonishing progress in the Biotechnology industry. A new era of innovation and entrepreneurship is Growing in Ile-de-France, leading to a... |
| 19.09.2023 | Which Biotech Startups are Transforming Ile-de-France’s Industry Landscape in 2023? | Ile-de-France, a densely populated region encompassing the French capital, Paris, is also emerging as a hotbed of cutting-edge biotechnology startups. With French companies developing innovative solutions across fields like life sciences, g... |
| 14.07.2023 | Paris-based EG 427 closes €18 million Series A to further develop gene therapies for chronic disease | - |
| 13.07.2023 | EG 427 Raises Additional €5M; Brings Total Series A to €18M | EG 427, a Paris, France-based biotechnology company developing pinpoint DNA medicine solutions, raised additional €5M in funding. The round, which brought the total amount to €18M, saw participation from a combination of existing investors ... |
| 13.07.2023 | Biotech Sensation EG 427 Clinches a Whopping 5 Million EUR in Series A Funding! | Key Takeaways: French biotech firm EG 427 secures 5 million EUR in a Series A funding round. The company is pioneering a unique approach in gene therapy, known as pinpoint gene therapy. With this latest injection of funds, EG 427 has raised... |
| 13.07.2023 | EG 427 announces final Series A closing, achieving €18 million in total funds raised | - |
| - | EG 427 | “PINPOINT DNA MEDICINES FOR CHRONIC DISEASES” |